Welcome to our dedicated page for NewcelX SEC filings (Ticker: NCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewcelX Ltd. (Nasdaq: NCEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. NewcelX reports under the Exchange Act on Form 20-F and furnishes current reports on Form 6-K, offering investors structured insight into its operations as a Swiss clinical-stage biopharmaceutical and biotechnology company focused on neurodegenerative and metabolic diseases.
Through these filings, readers can follow key corporate events connected to the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., which established NewcelX as a combined entity integrating cell-therapy platforms with neuroscience and small-molecule expertise. For example, a Form 6-K details the post-merger appointment of Kost Forrer Gabbay & Kasierer, a member of Ernst & Young, as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and describes the prior engagement and dismissal of CBIZ CPAs, P.C., along with references to previously disclosed material weaknesses.
On Stock Titan, NewcelX filings such as annual reports on Form 20-F, interim and event-driven Form 6-K submissions, and related exhibits can be viewed alongside AI-powered summaries. These summaries are designed to highlight essential elements of lengthy documents, helping users quickly identify information on topics like accounting firm changes, internal control disclosures, merger-related details, and other governance matters discussed in the filings.
Investors researching NCEL can use this page to monitor how NewcelX describes its business, risk factors, financial reporting framework, and post-merger integration steps over time. Real-time updates from EDGAR combined with AI-assisted overviews aim to make complex regulatory content more accessible without replacing the need to review the full original filings.
NewcelX Ltd. director Alexander Zwyer filed an initial Form 3 reporting derivative holdings in the company. He holds an option to purchase 50,143 ordinary shares at an exercise price of 7.6200, expiring on November 4, 2035.
A footnote explains that options to purchase 4,178 ordinary shares are currently vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to his continued service.
NewcelX Ltd. filed a current report describing that it has issued a press release announcing a strategic collaboration with Eledon Pharmaceuticals to advance its NCEL-101 program targeting Type 1 diabetes. The report also states that the first four paragraphs of this press release are incorporated by reference into several existing NewcelX shelf registration statements on Form F-3.
NewcelX Ltd. reported a peer-reviewed scientific review of Mazindol Immediate-Release/Sustained-Release (IR/SR) published in Clinical Drug Investigation. The company views this publication as independent validation of Mazindol ER’s clinical and mechanistic profile within its Contingent Value Right (CVR) framework.
NewcelX stated it is in advanced discussions with multiple potential partners on licensing or acquisition transactions for Mazindol ER, aiming to optimize terms and enhance value for CVR holders and shareholders. The company highlights over 20 years of research and intellectual property dating back to 2006, positioning Mazindol ER as a differentiated central nervous system asset targeting narcolepsy, ADHD, and substance use disorders.
NewcelX Ltd. furnished a 6-K announcing an updated corporate presentation and investor deck ahead of key spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The materials emphasize NewcelX’s primary focus on cell-based therapies for Type 1 Diabetes and its broader platform in metabolic and neurodegenerative diseases.
The updated presentation highlights recent scientific progress, clinical development priorities, and the company’s approach to restoring endogenous insulin production using regenerative medicine. It also introduces several new, internationally recognized members of the Scientific Advisory Board and leadership team, which NewcelX states will strengthen expertise across cell therapy development, translational medicine, clinical strategy, and commercialization.
NewcelX Ltd. filed a Form 6-K to share peer-reviewed, positive results from an international collaborative study on delivering stem cell–derived islets for Type 1 Diabetes without long-term immune suppression. The study, published in the diabetes journal Diabetology, used engineered scaffolds incorporating extracellular matrix from decellularized human pancreas to support encapsulated pluripotent stem cell–derived islets.
Results showed that when extracellular matrix was integrated into the scaffold, implanted islets functioned comparably to encapsulated islets delivered without a scaffold, suggesting biomaterial design and tissue microenvironment are critical for islet performance and could enable safer, retrievable delivery systems. The work was led by the Australian Foundation for Diabetes Research with support from the National Stem Cell Foundation of Australia and Breakthrough T1D.
The findings align with NewcelX’s IsletRx program, an investigational stem cell–derived islet therapy aimed at restoring insulin production in insulin-dependent diabetes while avoiding chronic immunosuppression, and reinforce Type 1 Diabetes as the company’s primary therapeutic focus.
NewcelX Ltd. (NLSP) reports auditor changes following its merger with Kadimastem. As part of post-merger integration, Kadimastem’s longtime auditor, Kost Forrer Gabbay & Kasierer, a member of Ernst & Young (EY), was appointed on November 20, 2025 as NewcelX’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
On November 17, 2025, after Audit Committee approval, the company dismissed CBIZ CPAs, P.C., which had replaced Marcum LLP on September 17, 2025 when CBIZ acquired Marcum’s attestation business. CBIZ CPAs did not issue an audit report on NewcelX’s financial statements. During CBIZ CPAs’ brief engagement there were no disagreements on accounting or auditing matters and no reportable events, other than previously disclosed material weaknesses in internal control related to staffing and segregation of duties.
The company notes that during the past two fiscal years and through November 20, 2025, it did not consult EY on specific accounting treatments or audit opinions and had no disagreements or reportable events with EY. CBIZ CPAs has provided a confirming letter to the SEC, filed as Exhibit 16.1.